updated 11/15/2005 11:04:03 AM ET 2005-11-15T16:04:03

High doses of the cholesterol-lowering drug Lipitor were no better at preventing recurrent heart attacks and heart-related deaths than regular doses of the competing drug Zocor, according to the latest study on efforts to aggressively treat heart conditions.

  1. Don't miss these Health stories
    1. Splash News
      More women opting for preventive mastectomy - but should they be?

      Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.

    2. Larry Page's damaged vocal cords: Treatment comes with trade-offs
    3. Report questioning salt guidelines riles heart experts
    4. CDC: 2012 was deadliest year for West Nile in US
    5. What stresses moms most? Themselves, survey says

The study, funded and conducted by Lipitor’s maker Pfizer Inc., was prepared for presentation Tuesday at an American Heart Association meeting in Dallas. It also appears in Wednesday’s Journal of the American Medical Association.

Many heart specialists recommend aggressively lowering LDL cholesterol levels, the bad kind, to help heart patients avoid future cardiovascular problems. So Pfizer tried that with a much higher dose of its statin drug, Lipitor.

Although the effort failed to reduce recurrent heart attacks, it seemed to be linked with fewer strokes, a finding that echoes earlier research.

The latest study involved 8,888 mostly male Scandinavian patients aged 61 on average who had previous heart attacks and were given either a high dose of Lipitor or a standard dose of Merck’s Zocor.

The researchers didn’t find the main difference they were looking for — fewer “major coronary events” in the Lipitor group during an average follow-up of almost five years. That category lumped together cardiovascular deaths, nonfatal heart attacks and nonfatal cardiac arrest. These events totaled 463 in the Zocor patients and 411 in the Lipitor patients, a difference that was not statistically significant.

The results can’t be considered a direct comparison because different doses of the competing drugs were used.

Dr. Terje Pedersen of Ulleval University Hospital in Oslo, Norway was the study’s lead author. Two Pfizer employees were among the co-authors.

© 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments